Oncology Views & Analysis

Views & Analysis

Oncology

At JPM2026, Astellas' chief strategy officer Adam Pearson walked pharmaphorum through the company’s four-pillared R&D strategy.

Oncology

Deep Dive editor Eloise McLennan speaks with Mohit Manrao, SVP, head of US oncology at AstraZeneca, and president of the AstraZeneca Foundation.

Oncology

Carlos Buesa, CEO of Oryzon Genomics, discusses exploring how epigenetics is reshaping the landscape of oncology and CNS therapies.

Oncology

With over 8,200 abstracts accepted, ASH 2025 showcased breakthroughs in sickle cell disease, platelet disorders, and next-generation cell therapies.

Oncology

Andrew Newland, former CEO of ANGLE, explains why live cell liquid biopsies should become standard in oncology.

Oncology

Perspective Therapeutics is advancing image‑guided, targeted alpha‑particle therapies (TATs). We spoke to Thijs Spoor at ESMO 2025 to find out more.